Vaped Cannabis Reduced the Severity of Naloxone-Precipitated Opioid Withdrawal in One Patient

In a single participant with opioid use disorder, pretreatment with vaped cannabis reduced naloxone-precipitated withdrawal severity in a dose-dependent manner without dangerous vital sign changes.

Jones, Jermaine D et al.·Experimental and clinical psychopharmacology·2025·very lowcase report
RTHC-06770Case reportvery low2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
case report
Evidence
very low
Sample
Not reported

What This Study Found

In one male participant (age 52) with OUD stabilized on oral morphine (120 mg/day), naloxone alone produced a COWS score of 22 at 30 minutes. Cannabis pretreatment at 12.5 mg reduced COWS to 17, and at 25 mg reduced it to 14. Combined naloxone and cannabis produced elevated heart rate and blood pressure, but not more than naloxone alone.

Key Numbers

N=1 (male, age 52). Morphine stabilization: 120 mg/day. COWS scores at T+30: naloxone alone=22; naloxone+cannabis 12.5mg=17; naloxone+cannabis 25mg=14. Dose-dependent reduction.

How They Did This

Proof-of-concept inpatient crossover study. Single participant completed 6 dose combinations of vaped cannabis (0, 12.5, 25 mg) and intranasal naloxone (0, 4 mg) during morphine stabilization (120 mg/day). Primary outcome: COWS withdrawal score.

Why This Research Matters

Fear of precipitated withdrawal is a major barrier to naloxone use. If cannabis can reduce withdrawal severity, combined naloxone-cannabis formulations could increase willingness to administer naloxone during overdose emergencies.

The Bigger Picture

This preliminary finding complements preclinical evidence that cannabinoids can reduce opioid withdrawal symptoms. If confirmed in larger studies, it could transform overdose reversal strategies.

What This Study Doesn't Tell Us

Single participant limits any conclusions. Major methodological redesign was needed during the study (reasons not detailed). Cannot generalize from n=1. Cannabis formulation and dose may not reflect real-world use. Inpatient setting is highly controlled.

Questions This Raises

  • ?Would this withdrawal reduction replicate in a larger sample?
  • ?Could a combined naloxone-cannabinoid nasal spray be developed for overdose reversal?

Trust & Context

Key Stat:
Cannabis pretreatment reduced opioid withdrawal severity score from 22 to 14 in one patient
Evidence Grade:
Single participant proof-of-concept provides the lowest level of evidence. Study required major methodological redesign, suggesting feasibility challenges.
Study Age:
2025 publication.
Original Title:
The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.
Published In:
Experimental and clinical psychopharmacology (2025)
Database ID:
RTHC-06770

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkTHC

Cite This Study

RTHC-06770·https://rethinkthc.com/research/RTHC-06770

APA

Jones, Jermaine D; Martinez, Suky; Arout, Caroline; Haney, Margaret; Castillo, Felipe; Manubay, Jeanne; Perez, Freymon; Luba, Rachel R; Comer, Sandra D. (2025). The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.. Experimental and clinical psychopharmacology. https://doi.org/10.1037/pha0000796

MLA

Jones, Jermaine D, et al. "The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.." Experimental and clinical psychopharmacology, 2025. https://doi.org/10.1037/pha0000796

RethinkTHC

RethinkTHC Research Database. "The effects of vaped cannabis on the severity of naloxone-pr..." RTHC-06770. Retrieved from https://rethinkthc.com/research/jones-2025-the-effects-of-vaped

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.